In the News
- Press Releases
- 2012
- 2011
- 2009
- 2010
- 2008
- February 6, 2008
- February 13, 2008
- February 20, 2008
- February 28, 2008
- March 4, 2008
- March 4, 2008 Fourth Quarter and Full Year 2007 Conference Call
- March 6, 2008
- April 21, 2008
- March 31, 2008
- May 1, 2008
- May 2, 2008
- May 7, 2008
- May 7, 2008
- May 16, 2008
- June 19, 2008
- July 18, 2008
- July 31, 2008
- August 4, 2008
- August 8, 2008
- August 8, 2008
- November 10, 2008
- August 12, 2008
- August 19, 2008
- October 22, 2008
- October 22, 2008
- October 27, 2008
- November 3, 2008
- November 3, 2008
- November 4, 2008
- Events
- For Media
- Investor Presentations
- Webcasts
Home » In the News » Press Releases » 2008 Press Releases » July 31, 2008
DUSA Pharmaceuticals, Inc. to Host Second Quarter Financial Results and Corporate Highlights Conference Call
For release at 8:00 a.m.
DUSA PHARMACEUTICALS, INC. TO HOST
SECOND QUARTER FINANCIAL RESULTS
AND CORPORATE HIGHLIGHTS CONFERENCE CALL
Wilmington, Mass. - July 31, 2008 - DUSA Pharmaceuticals, Inc.® (NASDAQ GM: DUSA) announces that its corporate highlights and second quarter financial results press release will be issued on Tuesday, August 5th at 6:30 a.m. to be followed by a conference call at 8:30 a.m.
Tuesday, August 5th - 8:30 a.m. Eastern
If calling from the US or Canada use the following toll-free number:
800.647.4314
Password - DUSA
For International callers use
435.871.6103
A recorded replay of the call will be available
North American callers 877.863.0350
International callers 858.244.1268
The call will be accessible on our web site approximately one hour following the call at www.dusapharma.com.
About DUSA Pharmaceuticals
DUSA Pharmaceuticals, Inc. is an integrated dermatology pharmaceutical company focused primarily on the development and marketing of its Levulan® Photodynamic Therapy (PDT) technology platform, and complementary dermatology products. Levulan PDT is currently approved for the treatment of Grade 1 or 2 actinic keratoses of the face or scalp, and is being studied for the treatment of acne. DUSA's other dermatology products include ClindaReachTM and Nicomide®. DUSA is also researching additional indications for internal uses of Levulan PDT. DUSA is based in Wilmington, Mass. Please visit the company's website at www.dusapharma.com for more information.
For further information contact:
Shari Lovell, Director, Shareholder Services
Tel: 978.657.7500 Ext. 1121